Core Insights - Basilea Pharmaceutica Ltd announced a USD 30 million sales milestone payment triggered by strong sales performance of its antifungal drug Cresemba in Europe [1][2] - Cresemba's global in-market sales reached USD 652 million from July 2024 to June 2025, reflecting a 27% year-on-year growth [2] Company Overview - Basilea is a commercial-stage biopharmaceutical company founded in 2000, headquartered in Switzerland, focused on developing innovative drugs for severe bacterial and fungal infections [4] - The company has successfully launched two hospital brands: Cresemba for invasive fungal infections and Zevtera for bacterial infections [4] Product Information - Cresemba (isavuconazole) is an intravenous and oral azole antifungal approved in over 70 countries, including the US and most EU member states [2][3] - It is indicated for the treatment of invasive aspergillosis and mucormycosis in patients for whom amphotericin B is inappropriate [3]

Core Insights - Basilea Pharmaceutica Ltd announced a milestone payment of USD 2.5 million due to strong sales performance of its antifungal Cresemba in the Asia Pacific region and China [1][2] - Cresemba's global in-market sales reached USD 562 million in 2024, reflecting a 19% year-on-year growth, establishing it as the largest branded antifungal for invasive fungal infections worldwide [3] Company Overview - Basilea is a commercial-stage biopharmaceutical company founded in 2000, focused on developing innovative drugs for severe bacterial and fungal infections [5] - The company has successfully launched two hospital brands: Cresemba for invasive fungal infections and Zevtera for bacterial infections [5] Product Information - Cresemba (isavuconazole) is available in over 70 countries and is approved in China for treating adult patients with invasive aspergillosis and invasive mucormycosis [4] - The license agreement for Cresemba includes coverage for Europe (excluding Nordic countries), China, and 16 countries in the Asia Pacific region [2]